Skip to main content
Journal cover image

Capromab Pendetide imaging of prostate cancer.

Publication ,  Journal Article
Haseman, MK; Rosenthal, SA; Polascik, TJ
Published in: Cancer Biother Radiopharm
April 2000

Capromab Pendetide imaging illustrates the successful translation of monoclonal antibody technology from the laboratory to the clinic. It provides a means of identifying otherwise occult soft tissue metastases in patients with adenocarcinoma of the prostate. When utilized with other clinical, pathological and laboratory findings, Capromab Pendetide imaging enables more accurate disease staging and monitoring than is afforded by other imaging modalities such as CT and MRI. In the primary disease setting Capromab Pendetide imaging should be reserved for use in patients with negative bone scans who are at high risk for metastatic disease based on such factors as advanced clinical stage, high Gleason score and significantly elevated serum PSA or alkaline phosphatase. Due to low sensitivity for small-volume disease, a negative Mab scan may not eliminate the need for a staging lymph node dissection but should encourage further consideration of local treatment options. Capromab Pendetide should be used with caution in patients at low risk for metastatic disease. Positive scan findings in low risk patients should be confirmed before altering the treatment plan since some false positive scans should be anticipated in a population with low disease prevalence. Capromab Pendetide imaging has not been shown to be reliable in determining the local extent of the primary tumor but new techniques involving co-registration of SPECT and CT images show promise in this regard. In the patient with recurrent disease following primary therapy, the predictive value of Capromab Pendetide imaging of the prostate or prostate fossa is limited, particularly following RT. Its more important role in this setting is to identify lymph node metastases in the high risk patient with a negative bone scan who might otherwise be a candidate for local salvage therapy. A large prospective study is needed for confirmation, but preliminary data suggest that Capromab Pendetide imaging is helpful in identifying those patients with PSA elevation after radical prostatectomy who are most likely to benefit from salvage RT. As with any imaging technique, Capromab Pendetide has strengths and weaknesses that must be understood to maximize patient benefit by utilizing the scan in clinical settings where it is most likely to be useful and least likely to be misleading. Capromab Pendetide is a technically demanding procedure best performed and interpreted at sites with experience and expertise.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Biother Radiopharm

DOI

ISSN

1084-9785

Publication Date

April 2000

Volume

15

Issue

2

Start / End Page

131 / 140

Location

United States

Related Subject Headings

  • Tomography, Emission-Computed, Single-Photon
  • Sensitivity and Specificity
  • Salvage Therapy
  • Radioisotope Teletherapy
  • Radioimmunodetection
  • Prostatic Neoplasms
  • Prostatectomy
  • Prostate-Specific Antigen
  • Preoperative Care
  • Nuclear Medicine & Medical Imaging
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Haseman, M. K., Rosenthal, S. A., & Polascik, T. J. (2000). Capromab Pendetide imaging of prostate cancer. Cancer Biother Radiopharm, 15(2), 131–140. https://doi.org/10.1089/cbr.2000.15.131
Haseman, M. K., S. A. Rosenthal, and T. J. Polascik. “Capromab Pendetide imaging of prostate cancer.Cancer Biother Radiopharm 15, no. 2 (April 2000): 131–40. https://doi.org/10.1089/cbr.2000.15.131.
Haseman MK, Rosenthal SA, Polascik TJ. Capromab Pendetide imaging of prostate cancer. Cancer Biother Radiopharm. 2000 Apr;15(2):131–40.
Haseman, M. K., et al. “Capromab Pendetide imaging of prostate cancer.Cancer Biother Radiopharm, vol. 15, no. 2, Apr. 2000, pp. 131–40. Pubmed, doi:10.1089/cbr.2000.15.131.
Haseman MK, Rosenthal SA, Polascik TJ. Capromab Pendetide imaging of prostate cancer. Cancer Biother Radiopharm. 2000 Apr;15(2):131–140.
Journal cover image

Published In

Cancer Biother Radiopharm

DOI

ISSN

1084-9785

Publication Date

April 2000

Volume

15

Issue

2

Start / End Page

131 / 140

Location

United States

Related Subject Headings

  • Tomography, Emission-Computed, Single-Photon
  • Sensitivity and Specificity
  • Salvage Therapy
  • Radioisotope Teletherapy
  • Radioimmunodetection
  • Prostatic Neoplasms
  • Prostatectomy
  • Prostate-Specific Antigen
  • Preoperative Care
  • Nuclear Medicine & Medical Imaging